In March 2018 the US Food and Drug Administration (FDA) issued a notice to interested stakeholders to comment on a proposed rule to create a tobacco product standard for nicotine. Over a year later, the FDA accepted for substantive review a modified risk tobacco product (MRTP) application for 22nd Century Group’s VLN (very low nicotine) product. This report analyses the advantages and disadvantages associated with very low nicotine products and considers their impact on the tobacco industry as a whole.
No. of pages: 6